ImmunogenX Invited To Present At The Medical Device & Investor Forum
11/18/2016 9:19:08 AM
The company presents its business plan at this select showcase
ImmunogenX, a biopharmaceutical company focused on the diagnosis and treatment of celiac
disease, announced that it was a select invited presenter at the Medical Device & Investor Forum
(MDIF) held in Irvine, CA on October 27-28, 2016. MDIF is the largest life science conference in
Southern California focused on high growth and innovation technology investment. OCTANe, the
organizer of the event, is dedicated to developing and advancing the technology business base in
Southern California. MDIF provided the opportunity for ImmunogenX to present its business plan in
the presence of leading venture capital firms as well as senior executives in the industry.
Jack Syage, CEO of ImmunogenX remarked, “MDIF is one of the leading forums in California
dedicated to bridging promising technology companies with sources to grow through investments and
strategic partnerships. We were ecstatic to be one of the very few companies selected to present at
this prestigious gathering.”
Bill Carpou, President and CEO of OCTANe commented, “ImmunogenX was chosen from a very
competitive pool of outstanding companies in the health care and medical technology field. They
impressed the panel with their mature technology, management team, business acumen, and investor
opportunity. It is also worth noting that ImmunogenX won the fast pitch competition in a preconference
event. We look forward to continuing our assistance to ImmunogenX on their road to success.”
ImmunogenX (a subsidiary of Immunogenics LLC) is a clinical-stage company founded in 2013 and is
supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research.
The company recently acquired Latiglutenase (ALV003) for celiac disease therapy, which is currently
in Phase 2 clinical trials. ImmunogenX is also developing a minimally-invasive diagnostic tool for
celiac disease management (CypCel) based on a clinically relevant metabolic marker compound that
can assess the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment.
For food safety, ImmunogenX is pioneering advanced mass spectrometry methods to identify and
measure physiologically relevant gluten peptide sequences found in wheat, barley, and rye and has
developed the first multiplexed analytical method to detect and quantify trace levels of gluten and
other allergens in food and consumer products.
comments powered by